| Pretargeted imaging and therapy M Altai, R Membreno, B Cook, V Tolmachev, BM Zeglis Journal of Nuclear Medicine 58 (10), 1553-1559, 2017 | 207 | 2017 |
| Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties H Wållberg, A Orlova, M Altai, SJ Hosseinimehr, C Widström, J Malmberg, ... Journal of Nuclear Medicine 52 (3), 461-469, 2011 | 103 | 2011 |
| The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin Z Varasteh, U Rosenström, I Velikyan, B Mitran, M Altai, H Honarvar, ... Molecules 19 (7), 10455-10472, 2014 | 85 | 2014 |
| HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [99mTc(CO)3]+-Labeled … C Hofström, M Altai, H Honarvar, J Strand, J Malmberg, ... Journal of medicinal chemistry 56 (12), 4966-4974, 2013 | 78 | 2013 |
| Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with 99mTc, 111In, and 125I C Hofström, A Orlova, M Altai, F Wångsell, T Gräslund, V Tolmachev Journal of medicinal chemistry 54 (11), 3817-3826, 2011 | 76 | 2011 |
| Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors M Altai, H Liu, H Ding, B Mitran, PH Edqvist, V Tolmachev, A Orlova, ... Journal of controlled release 288, 84-95, 2018 | 72 | 2018 |
| Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors H Honarvar, K Westerlund, M Altai, M Sandström, A Orlova, V Tolmachev, ... Theranostics 6 (1), 93, 2016 | 69 | 2016 |
| Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule A Orlova, M Malm, M Rosestedt, Z Varasteh, K Andersson, RK Selvaraju, ... European journal of nuclear medicine and molecular imaging 41, 1450-1459, 2014 | 61 | 2014 |
| Feasibility of affibody-based bioorthogonal chemistry–mediated radionuclide pretargeting M Altai, A Perols, M Tsourma, B Mitran, H Honarvar, M Robillard, ... Journal of Nuclear Medicine 57 (3), 431-436, 2016 | 60 | 2016 |
| Radionuclide therapy of HER2-expressing human xenografts using affibody-based peptide nucleic acid–mediated pretargeting: in vivo proof of principle K Westerlund, M Altai, B Mitran, M Konijnenberg, M Oroujeni, C Atterby, ... Journal of Nuclear Medicine 59 (7), 1092-1098, 2018 | 58 | 2018 |
| Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in … J Malmberg, A Perols, Z Varasteh, M Altai, A Braun, M Sandström, ... European journal of nuclear medicine and molecular imaging 39, 481-492, 2012 | 58 | 2012 |
| Comparative Evaluation of Radioiodine and Technetium‐Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors A Vorobyeva, O Bragina, M Altai, B Mitran, A Orlova, A Shulga, ... Contrast Media & Molecular Imaging 2018 (1), 6930425, 2018 | 56 | 2018 |
| Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with 68Ga … M Altai, J Strand, D Rosik, RK Selvaraju, A Eriksson Karlström, A Orlova, ... Bioconjugate chemistry 24 (6), 1102-1109, 2013 | 54 | 2013 |
| Comparative evaluation of two DARPin variants: effect of affinity, size, and label on tumor targeting properties S Deyev, A Vorobyeva, A Schulga, G Proshkina, R Guler, J Lofblom, ... Molecular pharmaceutics 16 (3), 995-1008, 2019 | 52 | 2019 |
| Radionuclide tumor targeting using ADAPT scaffold proteins: aspects of label positioning and residualizing properties of the label S Lindbo, J Garousi, B Mitran, M Altai, J Buijs, A Orlova, S Hober, ... Journal of Nuclear Medicine 59 (1), 93-99, 2018 | 47 | 2018 |
| In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors M Altai, Z Varasteh, K Andersson, A Eek, O Boerman, A Orlova Cancer Biotherapy and Radiopharmaceuticals 28 (3), 187-195, 2013 | 44 | 2013 |
| Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26 B Mitran, SS Rinne, MW Konijnenberg, T Maina, BA Nock, M Altai, ... International Journal of Cancer 145 (12), 3347-3358, 2019 | 43 | 2019 |
| Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules V Tolmachev, M Altai, M Sandström, A Perols, AE Karlström, ... Bioconjugate chemistry 22 (5), 894-902, 2011 | 40 | 2011 |
| Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX: 1 affibody molecule H HONARvAR, J Garousi, E Gunneriusson, I HöIDéN-GUTHENbERG, ... International journal of oncology 46 (2), 513-520, 2015 | 38 | 2015 |
| Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with 18F … D Rosik, A Thibblin, G Antoni, H Honarvar, J Strand, RK Selvaraju, M Altai, ... Bioconjugate chemistry 25 (1), 82-92, 2014 | 33 | 2014 |
John LöfblomProfessor in Combinatorial Protein Engineering, KTH Royal Institute of TechnologyVerified email at kth.se
